Clinical Trial Update: A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Letermovir (Prevymis) to prevent cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation in pediatric patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Solid Tumor

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Children's Oncology Group | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 3 | Status: RECRUITING